These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 30048166)

  • 21. Prospectively recorded and MedDRA-coded safety data of intravenous methylprednisolone therapy in Graves' orbitopathy.
    Riedl M; Kolbe E; Kampmann E; Krämer I; Kahaly GJ
    J Endocrinol Invest; 2015 Feb; 38(2):177-82. PubMed ID: 25576458
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influence of Methylprednisolone Pulse Therapy on Liver Function in Patients with Graves' Orbitopathy.
    Miśkiewicz P; Jankowska A; Brodzińska K; Milczarek-Banach J; Ambroziak U
    Int J Endocrinol; 2018; 2018():1978590. PubMed ID: 30420883
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The influence of Graves' orbitopathy treatment with intravenous glucocorticoids on adrenal function.
    Ambroziak U; Bluszcz G; Bednarczuk T; Miśkiewicz P
    Endokrynol Pol; 2017; 68(4):430-433. PubMed ID: 28604944
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Decrease in Bone Formation and Bone Resorption during Intravenous Methylprednisolone Pulse Therapy in Patients with Graves' Orbitopathy.
    Rymuza J; Gutowska K; Kurpios-Piec D; Struga M; Miśkiewicz P
    J Clin Med; 2022 Aug; 11(17):. PubMed ID: 36078937
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sight-threatening Graves' orbitopathy: Twenty years' experience of a multidisciplinary thyroid-eye outpatient clinic.
    Tramunt B; Imbert P; Grunenwald S; Boutault F; Caron P
    Clin Endocrinol (Oxf); 2019 Jan; 90(1):208-213. PubMed ID: 30339291
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic factors for thyroid-stimulating immunoglobulin normalization in moderate-to-severe Graves' orbitopathy: a 36-month longitudinal study.
    Park J; Son Y; Kim J; Kim S; Choi HY
    BMC Ophthalmol; 2024 Aug; 24(1):361. PubMed ID: 39169342
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early use of steroid-sparing agents in the inactivation of moderate-to-severe active thyroid eye disease: a step-down approach.
    Sipkova Z; Insull EA; David J; Turner HE; Keren S; Norris JH
    Clin Endocrinol (Oxf); 2018 Dec; 89(6):834-839. PubMed ID: 30103255
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Systemic safety analysis of mycophenolate in Graves' orbitopathy.
    Lee ACH; Riedl M; Frommer L; Diana T; Kahaly GJ
    J Endocrinol Invest; 2020 Jun; 43(6):767-777. PubMed ID: 31834613
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical review: Intravenous glucocorticoids for Graves' orbitopathy: efficacy and morbidity.
    Zang S; Ponto KA; Kahaly GJ
    J Clin Endocrinol Metab; 2011 Feb; 96(2):320-32. PubMed ID: 21239515
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment with Intravenous Methylprednisolone in Patients with Graves' Orbitopathy Significantly Affects Adrenal Function: Assessment of Serum, Salivary Cortisol and Serum Dehydroepiandrosterone Sulfate.
    Pelewicz K; Szewczyk S; Miśkiewicz P
    J Clin Med; 2020 Oct; 9(10):. PubMed ID: 33050327
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of mild, moderate-to-severe and very severe Graves' orbitopathy.
    Marcocci C; Marinò M
    Best Pract Res Clin Endocrinol Metab; 2012 Jun; 26(3):325-37. PubMed ID: 22632369
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum concentrations of HGF and IL-8 in patients with active Graves' orbitopathy before and after methylprednisolone therapy.
    Nowak M; Siemińska L; Karpe J; Marek B; Kos-Kudła B; Kajdaniuk D
    J Endocrinol Invest; 2016 Jan; 39(1):63-72. PubMed ID: 26062519
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of B cell depletion therapy on anti-TSH receptor antibodies and clinical outcome in glucocorticoid-refractory Graves' orbitopathy.
    Mitchell AL; Gan EH; Morris M; Johnson K; Neoh C; Dickinson AJ; Perros P; Pearce SH
    Clin Endocrinol (Oxf); 2013 Sep; 79(3):437-42. PubMed ID: 23320840
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves' orbitopathy (MINGO): a randomised, observer-masked, multicentre trial.
    Kahaly GJ; Riedl M; König J; Pitz S; Ponto K; Diana T; Kampmann E; Kolbe E; Eckstein A; Moeller LC; Führer D; Salvi M; Curro N; Campi I; Covelli D; Leo M; Marinò M; Menconi F; Marcocci C; Bartalena L; Perros P; Wiersinga WM;
    Lancet Diabetes Endocrinol; 2018 Apr; 6(4):287-298. PubMed ID: 29396246
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Success Treatment of Severe and Active Graves' Orbitopathy with Tocilizumab After Thyroidectomy and Maximum Dose of Intravenous Methylprednisolone.
    Pramono LA
    Acta Med Indones; 2023 Oct; 55(4):475-477. PubMed ID: 38213047
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Statins in Graves Orbitopathy: A New Therapeutic Tool.
    Lanzolla G; Comi S; Cosentino G; Pakdel F; Marinò M
    Ophthalmic Plast Reconstr Surg; 2023 Dec; 39(6S):S29-S39. PubMed ID: 38054983
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Determinants of liver damage associated with intravenous methylprednisolone pulse therapy in Graves' ophthalmopathy.
    Le Moli R; Baldeschi L; Saeed P; Regensburg N; Mourits MP; Wiersinga WM
    Thyroid; 2007 Apr; 17(4):357-62. PubMed ID: 17465867
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Statins for Graves' orbitopathy (STAGO): a phase 2, open-label, adaptive, single centre, randomised clinical trial.
    Lanzolla G; Sabini E; Leo M; Menconi F; Rocchi R; Sframeli A; Piaggi P; Nardi M; Marcocci C; Marinò M
    Lancet Diabetes Endocrinol; 2021 Nov; 9(11):733-742. PubMed ID: 34592164
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study.
    Salvi M; Vannucchi G; Currò N; Campi I; Covelli D; Dazzi D; Simonetta S; Guastella C; Pignataro L; Avignone S; Beck-Peccoz P
    J Clin Endocrinol Metab; 2015 Feb; 100(2):422-31. PubMed ID: 25494967
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dysthyroid optic neuropathy: emerging treatment strategies.
    Pelewicz-Sowa M; Miśkiewicz P
    J Endocrinol Invest; 2023 Jul; 46(7):1305-1316. PubMed ID: 36802028
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.